Holen Sie sich die Stockscreener-App
1.75
44.79%
-1.42
Handel nachbörslich:
1.75
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.17
Offen:
$1.94
24-Stunden-Volumen:
111.99M
Relative Volume:
9.94
Marktkapitalisierung:
$1.17B
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-440.22M
KGV:
-1.0479
EPS:
-1.67
Netto-Cashflow:
$-400.48M
1W Leistung:
-50.00%
1M Leistung:
-46.48%
6M Leistung:
-83.47%
1J Leistung:
-86.99%
1-Tages-Spanne:
$1.65
$1.985
1-Wochen-Bereich:
$1.65
$3.73
52-Wochen-Spanne:
$1.65
$13.20
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
1.75 | 1.17B | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Market Today: Trade Desk Surges on Strong Earnings; Iovance Biotherapeutics Plummets - GuruFocus
Securities Fraud Investigation Into Iovance Biotherapeutics, Inc. (IOVA) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi - Endpoints News
Iovance Biotherapeutics (IOVA) Shares Plummet on Revenue Miss and Forecast Cut - GuruFocus
Iovance falls after guidance cut, revenue miss - MSN
Iovance stock falls after guidance cut, Q1 miss (IOVA:NASDAQ) - Seeking Alpha
Why Iovance Biotherapeutics Stock Is Crashing Today - AOL.com
Iovance Biotherapeutics (IOVA) Downgraded by JMP Securities | IOVA Stock News - GuruFocus
Iovance Biotherapeutics Stock Sinks 46%. Here’s Why the Biotech Is Tumbling. - Barron's
Why Iovance (IOVA) Stock Is Plummeting Today - GuruFocus
Iovance Biotherapeutics (IOVA) Stock Rating Maintained, Price Target Lowered by Chardan Capital | IOVA Stock News - GuruFocus
Iovance Biotherapeutics (IOVA) Price Target Cut by TD Cowen | IOVA Stock News - GuruFocus
Expert Outlook: Iovance Biotherapeutics Through The Eyes Of 9 Analysts - Benzinga
No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed (NASDAQ:IOVA) - Seeking Alpha
Sector Update: Health Care - marketscreener.com
Baird Downgrades Iovance Biotherapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $20 - marketscreener.com
Iovance Biotherapeutics (IOVA) Price Target Cut Following Revised Revenue Outlook | IOVA Stock News - GuruFocus
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut - Nasdaq
Iovance Biotherapeutics (IOVA) Price Target Lowered by HC Wainwright | IOVA Stock News - GuruFocus
Iovance Biotherapeutics (IOVA) Target Price Reduced but Buy Rating Maintained | IOVA Stock News - GuruFocus
Iovance Biotherapeutics: Q1 Earnings Snapshot - New Haven Register
Iovance Biotherapeutics (IOVA) Downgraded Amid Concerns Over Launch Complexities | IOVA Stock News - GuruFocus
Iovance Biotherapeutics Q1 Loss Narrows, Revenue Rises - marketscreener.com
Iovance Biotherapeutics Reports Q1 2025 Financial Results - TipRanks
Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy ... - Yahoo Finance
Decoding Iovance Biotherapeutics Inc (IOVA): A Strategic SWOT Insight - GuruFocus
(IOVA) Technical Data - news.stocktradersdaily.com
Iovance Biotherapeutics (IOVA) Projects Revenue Growth and Expanded Market Reach - GuruFocus
Iovance Biotherapeutics: Buy Rating Amid Signs of Recovery and Growth Potential - TipRanks
Iovance revises 2025 revenue guidance to $250M-$300M amid ATC expansion - MSN
Iovance Biotherapeutics earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Iovance Biotherapeutics misses Q1 2025 EPS forecasts, stock drops - Investing.com
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
IOVANCE BIOTHERAPEUTICS, INC. SEC 10-Q Report - TradingView
Iovance Biotherapeutics (IOVA) Q1 2025 Earnings Miss Estimates - GuruFocus
Iovance (IOVA) Misses Q1 Revenue Expectations, Projects Growth in Q2 | IOVA Stock News - GuruFocus
Iovance Biotherapeutics Inc Reports Q1 2025 Earnings: EPS Misses at -$0.36, Revenue Falls Short at $49.3 Million - GuruFocus
Iovance Biotherapeutics (IOVA) Sees Increased Options Activity A - GuruFocus
Earnings Flash (IOVA) Iovance Biotherapeutics Reports Q1 Revenue $49.3M, vs. FactSet Est of $82.4M - marketscreener.com
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 - GlobeNewswire
Uncovering Potential: Iovance Biotherapeutics's Earnings Preview - Nasdaq
Iovance Biotherapeutics (NasdaqGM:IOVA) Sees 3% Price Increase Over Last Month - Yahoo Finance
Iovance Biotherapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Iovance Biotherapeutics’ SWOT analysis: promising immunotherapy stock faces challenges - Investing.com
My 3 Favorite Stocks to Buy Right Now - The Motley Fool
With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space - insights.citeline.com
Iovance Biotherapeutics (IOVA) Nears Profitability with 2027 Projection - GuruFocus
Iovance Biotherapeutics (IOVA) to Announce Q1 2025 Financial Results - GuruFocus
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 - The Manila Times
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 | IOVA Stock News - GuruFocus
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):